Filippo Mulinacci, chief business officer at Araris Biotech since 2022, played a key role in the company's acquisition by Taiho Pharma for up to $1.14 billion. His career began in a research capacity at Serono post-education, evolving through a PhD in pharmaceutical sciences and an MBA, which equipped him with strategic and financial skills necessary for biopharma. Mulinacci stresses the importance of business understanding in the field, having leveraged his diverse academic background to succeed in corporate roles, especially emphasizing the significance of licensing within the biopharmaceutical landscape.
My first job after graduating with my MSc was as a research associate at the biotechnology company Serono. Going straight into a biotech company was a great career move.
For me, the key takeaways were gaining an understanding of business strategy, marketing, frameworks and finance, including accounting, corporate finance and valuation.
I joined Roche as a global business-development and licensing associate right after finishing my MBA in 2011. Licensing in the biopharma industry is crucial.
The deal with Taiho Pharma was a significant milestone, reflecting not only the value of Araris Biotech but also the strategic positioning in the oncology space.
Collection
[
|
...
]